Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
AOD-9604 vs Retatrutide
An educational, source-based comparison of AOD-9604 and Retatrutide — how each peptide works, what it's researched for, and what to know before going deeper.
A modified 16-amino-acid fragment (177–191) of human growth hormone, engineered to retain the lipolytic activity of GH without its growth or insulin-resistance effects. Research suggests it stimulates lipolysis and inhibits lipogenesis.
- Obesity (clinical trials did not meet endpoints)
- Osteoarthritis / cartilage repair (current research direction)
- Localized adipose research
- • Not FDA-approved as a therapeutic.
- • Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
A synthetic peptide that simultaneously agonizes GLP-1, GIP, and glucagon receptors. The glucagon component is hypothesized to add energy expenditure on top of the appetite suppression and insulinotropic effects of GLP-1/GIP.
- Obesity and weight loss (Phase 3)
- Type 2 diabetes
- NAFLD/MASH
- • Investigational; not FDA-approved (Phase 3 ongoing).
- • GI side effects common, similar to other incretin therapies.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| AOD-9604 | AOD9604 in obesity: phase 2b results | Obesity | 2010 | Did not achieve significant weight loss vs. placebo in primary endpoint. |
| Retatrutide | Triple-hormone-receptor agonist retatrutide for obesity | New England Journal of Medicine | 2023 | Phase 2 trial showed up to ~24% body weight reduction at 48 weeks. |
Side-effect & safety grid
- Not FDA-approved as a therapeutic.
- Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
- Investigational; not FDA-approved (Phase 3 ongoing).
- GI side effects common, similar to other incretin therapies.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
AOD-9604 vs Retatrutide — Key differences
- Class: AOD-9604 is classified as Metabolic · Lipolysis, while Retatrutide is Metabolic · Incretin.
- Primary research focus: AOD-9604 — obesity (clinical trials did not meet endpoints); Retatrutide — obesity and weight loss (phase 3).
- Tag: Fat loss vs Weight loss.